IMMX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
IMMX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Immix Biopharma's Book Value per Share for the quarter that ended in Mar. 2024 was $1.06.
During the past 12 months, Immix Biopharma's average Book Value per Share Growth Rate was 25.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
For the Biotechnology subindustry, Immix Biopharma's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Immix Biopharma's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where Immix Biopharma's 3-Year Book Growth Rate falls into.
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
Immix Biopharma (NAS:IMMX) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
Thank you for viewing the detailed overview of Immix Biopharma's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Jason Hsu | director | 11400 WEST OLYMPIC BLVD., SUITE 200, LOS ANGELES CA 90064 |
Carey Ng | director | 11400 WEST OLYMPIC BLVD., SUITE 200, LOS ANGELES CA 90064 |
Helen C. Adams | director | 15378 AVENUE OF SCIENCE, STE 100, SAN DIEGO CA 92128 |
Melissa Jane Buchan | director | 1920 MAIN STREET, SUITE 500, IRVINE CA 92614 |
Magda Marquet | director | ALTHEADX INC., 3550 DUNHILL STREET, SAN DIEGO CA 92121 |
Yekaterina Chudnovsky | director, 10 percent owner | C/O ELICIO THERAPEUTICS, INC., 451 D STREET, 5TH FLOOR, SUITE 501, BOSTON MA 02210 |
Ilya M Rachman | director, officer: CEO and Chairman | 11400 WEST OLYMPIC BLVD.,, SUITE 200, LOS ANGELES CA 90064 |
Gabriel S Morris | director, officer: Chief Financial Officer | 11400 WEST OLYMPIC BLVD.,, SUITE 200, LOS ANGELES CA 90064 |
Sean Senn | 10 percent owner | 11400 WEST OLYMPIC BLVD., SUITE 200, LOS ANGELES CA 90064 |
Vladimir P Torchilin | officer: Scientific Co-Founder | 11400 WEST OLYMPIC BLVD.,, SUITE 200, LOS ANGELES CA 90064 |
Graham Ross | officer: CMO & Head of Clinical Dev. | 11400 WEST OLYMPIC BLVD., SUITE 200, LOS ANGELES CA 90064 |
From GuruFocus
By sperokesalga sperokesalga • 03-31-2023
By Marketwired • 08-18-2023
By Marketwired • 10-03-2023
By sperokesalga sperokesalga • 05-03-2023
By Marketwired • 09-01-2023
By Marketwired • 07-25-2023
By sperokesalga sperokesalga • 03-23-2023
By Marketwired • 07-17-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.